The state will study whether Rocklanders would be better off having their water supply managed by municipalities rather than the corporation that now serves about 300,000 out of some 329,000 county ...

TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic ...

SAN FRANCISCO--(BUSINESS WIRE)--Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis in children, “Prospective ...

Tsukuba, Japan—Primary sclerosing cholangitis (PSC) is a chronic, progressive inflammatory disease characterized by fibrosis and bile duct stricturing, which ultimately leads to cirrhosis and liver ...

TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, ...

SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the topline results of the study of HTD1801 in ...

Shares of Pliant Therapeutics, Inc. PLRX gained 14.3% on Sep 26 after the company announced that its mid-stage study on lead pipeline candidate bexotegrast was successful. The phase IIa INTEGRIS-PSC ...

In a report released today, Ed Arce from H.C. Wainwright maintained Pliant Therapeutics (PLRX – Research Report) to a Buy, with a price target of $52.00. Ed Arce’s Buy rating for Pliant Therapeutics ...